Effect of HMG-CoA reductase inhibitors on activation of human γδT cells induced by Mycobacterium tuberculosis antigens

References

• Isakov, N., Wange, R. L., Samelson, L. E. The role of tyrosine kinases and phosphotyrosine-containing recognition motifs in regulation of the T cell-antigen receptor-mediated signal transduction pathway. J Leukoc Biol. 1994, 55, 265–271.
   Google Scholar
• Cantrell, D. A. T cell antigen receptor signal transduction pathways. Cancer Surv. 1996, 27, 165–175.
   PubMedGoogle Scholar
• Simons, K., Toomre, D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000, 1, 31–39.
   PubMed Web of Science ®Google Scholar
• Alonso, M. A., Millan, J. The role of lipid rafts in signalling and membrane trafficking in T lymphocytes. J Cell Sci. 2001, 114, 3957–3965.
   PubMed Web of Science ®Google Scholar
• Janes, P. W., Ley, S. C., Magee, A. I. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J Cell Biol. 1999, 147, 447–461.
   PubMed Web of Science ®Google Scholar
• Schade, A. E., Levine, A. D. Lipid raft heterogeneity in human peripheral blood T lymphoblasts: A mechanism for regulating the initiation of TCR signal transduction. J Immunol. 2002, 168, 2233–2239.
   PubMed Web of Science ®Google Scholar
• Tuosto, L., Parolini, I., Schroder, S., et al. Organization of plasma membrane functional rafts upon T cell activation. Eur J Immunol. 2001, 31, 345–349.
   PubMed Web of Science ®Google Scholar
• Lennernas, H., Fager, G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997, 32, 403–425.
   PubMed Web of Science ®Google Scholar
• Jasinska, M., Owczarek, J., Orszulak-Michalak, D. Statins: A new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep. 2007, 59, 483–499.
   PubMed Web of Science ®Google Scholar
• Ornish, D. Statins and the soul of medicine. Am J Cardiol. 2002, 89, 1286–1290.
   Google Scholar
• Shovman, O., Levy, Y., Gilburd, B., Shoenfeld, Y. Antiinflammatory and immunomodulatory properties of statins. Immunol Res. 2002, 25, 271–285.
   PubMed Web of Science ®Google Scholar
• Danesh, F. R., Anel, R. L., Zeng, L., et al. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz). 2003, 51, 139–148.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio, L. M., Tunon, J., Martin-Ventura, J. L., Egido, J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003, 63, 12–23.
   PubMed Web of Science ®Google Scholar
• Mach, F. Immunosuppressive effects of statins. Atheroscler Suppl. 2002, 3, 17–20.
   PubMedGoogle Scholar
• Fehr, T., Kahlert, C., Fierz, W., et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004, 175, 83–90.
   Google Scholar
• Mach, F. Statins as immunomodulatory agents. Circulation. 2004, 109, II15–17.
   PubMed Web of Science ®Google Scholar
• Kobashigawa J. A. Statins as immunosuppressive agents. Liver Transpl. 2001, 7, 559–561.
   Google Scholar
• Ladel, C. H., Hess, J., Daugelat, S., et al. Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against Mycobacterium bovis bacillus Calmette Guerin: Studies with T cell receptor-deficient mutant mice. Eur J Immunol. 1995, 25, 838–846.
   Google Scholar
• Li, B., Rossman, M. D., Imir, T., et al. Disease-specific changes in gammadelta T cell repertoire and function in patients with pulmonary tuberculosis. J Immunol. 1996, 157, 4222–4229.
   Google Scholar
• Boom, W. H., Balaji, K. N., Nayak, R., et al. Characterization of a 10- to 14-kilodalton protease-sensitive Mycobacterium tuberculosis H37Ra antigen that stimulates human gamma delta T cells. Infect Immun. 1994, 62, 5511–5518.
   Google Scholar
• Watanabe, H., Narumi, K., Stewart, C. C., et al. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity. Anticancer Res. 1992, 12, 1925–1933.
   PubMed Web of Science ®Google Scholar
• Touraine, J. L., Hadden, J. W., Touraine, F., et al. A. Phorbol myristate acetate: A mitogen selective for a T-lymphocyte subpopulation. J Exp Med. 1977, 145, 460–465.
   PubMed Web of Science ®Google Scholar
• Popma, S. H., Griswold, D. E., Li, L. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecific T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. Int Immunopharmacol. 2005, 5, 155–162.
   Google Scholar
• Marzio, R., Mauel, J., Betz-Corradin, S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol. 1999, 21, 565–582.
   PubMed Web of Science ®Google Scholar
• Kusama, T., Mukai, M., Ayaki, M., et al. Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Int J Oncol. 2003, 23, 1173–1178.
   Google Scholar
• Weitz-Schmidt, G., Welzenbach, K., Dawson, J., Kallen, J. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: Molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J Biol Chem. 2004, 279, 46764–46771.
   PubMed Web of Science ®Google Scholar
• Goldman, F., Hohl, R. J., Crabtree, J., et al. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood. 1996, 88, 4611–4619.
   Google Scholar
• Hillyard, D. Z., Cameron, A. J., McIntyre, A. H., et al. Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin. Clin Exp Pharmacol Physiol. 2002, 29, 673–678.
   PubMed Web of Science ®Google Scholar
• Lefer, D. J. Statins as potent antiinflammatory drugs. Circulation. 2002, 106, 2041–2042.
   PubMed Web of Science ®Google Scholar
• Hillyard, D. Z., Jardine, A. G., McDonald, K. J., Cameron, A. J. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. Atherosclerosis. 2004, 172, 219–228.
   PubMed Web of Science ®Google Scholar
• Hillyard, D. Z., Cameron, A. J., McDonald, K. J., et al. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis. 2004, 175, 305–313.
   PubMed Web of Science ®Google Scholar
• Choi, M., Rolle, S., Rane, M., et al. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int. 2003, 63, 96–106.
   PubMedGoogle Scholar
• Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001, 7, 687–692.
   PubMed Web of Science ®Google Scholar
• Peng, X., Jin, J., Giri, S., et al. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol. 2006, 178, 130–139.
   PubMedGoogle Scholar
• Youssef, S., Stuve, O., Patarroyo, J. C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002, 420, 78–84.
   PubMed Web of Science ®Google Scholar
• Arnaud, C., Burger, F., Steffens, S., et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: New evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005, 25, 1231–1236.
   PubMed Web of Science ®Google Scholar
• Fessler, M. B., Arndt, P. G., Frasch, S. C., et al. Lipid rafts regulate lipopolysaccharide-induced activation of Cdc42 and inflammatory functions of the human neutrophil. J Biol Chem. 2004, 279, 39989–39998.
   Google Scholar
• Li, Q., Wang, M., Tan, L., et al. Docosahexaenoic acid changes lipid composition and interleukin-2 receptor signaling in membrane rafts. J Lipid Res. 2005, 46, 1904–1913.
   PubMed Web of Science ®Google Scholar
• Chan, A. C., Desai, D. M., Weiss, A. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol. 1994, 12, 555–592.
   PubMed Web of Science ®Google Scholar
• McGuire T. F., Corey, S. J., Sebti, S. M. Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptor. J Biol Chem. 1993, 268, 22227–22230.
   Google Scholar
• Shakarjian, M. P., Eiseman, E., Penhallow, R. C., Bolen, J. B. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibition in a rat mast cell line. Impairment of tyrosine kinase-dependent signal transduction and the subsequent degranulation response. J Biol Chem. 1993, 268, 15252–15259.
   PubMedGoogle Scholar